DarioHealth (NASDAQ: DRIO), a leader in the global digital therapeutics (“DTx”) market, has launched a new product: the Upright GO S. The new biofeedback sensor is designed to improve access to back health solutions and increase membership on Dario’s integrated personalization platform. The wearable device features DRIO’s proprietary biofeedback technologies and is a strategic piece of the DarioHealth’s planned growth strategy for increasing platform membership across both business partnerships and consumer channels. The product announcement noted that DRIO currently has an estimated 185,000 members across its integrated suite of digital therapeutics. Back and neck pain is a growing health concern in the United States, with a recent survey of Dario users indicating that 78% of those who responded reported that the increase in sedentary activities during the day is negatively impacting their health. The Upright GO S is designed to meet that growing consumer need as it addresses the demand for more accessible musculoskeletal care. “One of the strengths of Upright’s sensor-based solutions is the successful track record of consumer adoption,” said DarioHealth CEO Erez Raphael in the press release. “The Upright GO S continues that legacy by offering a more affordable option to make digital health solutions accessible to a larger number of people in support of our mission and membership growth strategy.”
To view the full press release, visit https://ibn.fm/n59b1
About DarioHealth Corp.
DarioHealth is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. Dario’s next-generation, AI-powered, digital therapeutic solutions support more than just an individual’s disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software and coaching to help individuals improve health and sustain meaningful outcomes. Dario offers one of the highest-rated diabetes and hypertension solutions on the market. The company’s cross-functional team operates at the intersection of life sciences, behavioral science and software technology and is rapidly expanding into new chronic conditions and geographic markets, using a performance-based approach to improve its users’ health. Dario makes the right thing to do the easy thing to do. For more information about the company, please visit www.DarioHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.
